<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01484574</url>
  </required_header>
  <id_info>
    <org_study_id>SRPL/CLI/10-11/001</org_study_id>
    <nct_id>NCT01484574</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease</brief_title>
  <official_title>A Non-randomized, Open Label, Multicentric, Dose Ranging , Phase II Study Assessing the Efficacy and Safety of Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With Critical Limb Ischemia Due to Buerger's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stempeutics Research Pvt Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stempeutics Research Pvt Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, non-randomized, dose ranging study to evaluate the safety and efficacy
      of different doses of Stempeucel in critical limb ischemia patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of the rest pain</measure>
    <time_frame>6 months</time_frame>
    <description>Rest pain will be measured using rest pain scale (0 to10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Healing of ulcerations or reduction of ulcer area in the target limb</measure>
    <time_frame>6 months</time_frame>
    <description>Complete ulcer healing defined as complete epithelisation of ulcer and partial ulcer healing as at least 30% decrease in ulcer size.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relief of the rest pain</measure>
    <time_frame>24 months</time_frame>
    <description>Rest pain will be measured using rest pain scale (0 to 10)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Healing of ulcerations or reduction of ulcer area in the target limb</measure>
    <time_frame>24 months</time_frame>
    <description>Complete ulcer healing defined as complete epithelisation of ulcer and partial ulcer healing as at least 30% decrease in ulcer size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain free walking distance</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major amputation free survival</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle brachial pressure index (ABPI) - measured by Doppler</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in transcutaneous partial oxygen pressure (TcPO2)</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life by King's College VascuQOL questionnaire</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenesis - collateral blood vessels by Magnetic resonance angiogram (MRA)</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The type of adverse events AE(s), number of AE(s) and proportion of patients with AE(s).</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical laboratory parameters</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination findings and assessment of vital signs</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of electrocardiogram (ECG) parameters</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Buerger's Disease</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stempeucel - CLI will be administered at the lowest dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stempeucel - CLI will be administered at intermediate dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard protocol of care alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Stem Cells</intervention_name>
    <description>Single intramuscular administration of low dose of stem cells</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Stempeucel - CLI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Stem Cells</intervention_name>
    <description>Single intramuscular administration of intermediate dose of stem cells</description>
    <arm_group_label>Intermediate dose</arm_group_label>
    <other_name>Stempeucel - CLI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Buerger's disease as diagnosed by Shionoya criteria

          -  Males or females (willing to use accepted methods of contraception during the course
             of the study) in the age group of 18-65 yrs

          -  Established CLI in the study limb, clinically and hemodynamically confirmed as per
             Rutherford- III-5

          -  Patients in Rutherford- III-6 if gangrene extending maximally up to the head of
             metatarsal but limited to toes (Patients with wet gangrene must undergo wound
             debridement / amputation before screening)

          -  Patients having infrapopliteal occlusive disease with rest pain and ischemic
             ulcer/necrosis, who are not eligible for or have failed traditional revascularization
             treatment as per the investigators judgment (No option patients)

          -  Ankle Brachial Pressure Index (ABPI) ≤ 0.6 or ankle pressure ≤ 50 mm Hg or TcPO2 ≤ 40
             mmHg in the foot of the study limb

          -  Patients who are able to understand the requirements of the study, and willing to
             provide voluntary written informed consent and video consent, abide by the study
             requirements, and agree to return for required follow-up visits

        Exclusion Criteria:

          -  Patients with CLI indicated for major amputation during screening

          -  Atherosclerotic PAD

          -  Ulcers with exposure of tendon and/bone in the shin region

          -  Previous above transmetatarsal amputation in study limb

          -  Any Lumbar sympathectomy procedure performed less than 90 days prior to the screening

          -  Patients with gait disturbance for reasons other than CLI

          -  Diagnosis of diabetes mellitus (type 1 or type 2)

          -  Patients having left ventricular ejection fraction &lt; 35%

          -  Patients suffering from clinically relevant peripheral neuropathy

          -  History of Stroke or myocardial infarction

          -  Patients who are contraindicated for MRA

          -  Patients with deep vein thrombosis in any limb

          -  Patients who have clinically serious and/or unstable inter-current infection, medical
             illnesses or conditions that are uncontrolled or whose control, in the opinion of the
             Investigator, may be jeopardized by participation in this study or by the
             complications of this therapy

          -  Documented terminal illness or cancer or any concomitant disease process with a life
             expectancy of &lt;1 year

          -  Patients already enrolled in another investigational drug trial or completed within 3
             months or those who have participated in any stem cell clinical trial

          -  Patient with known hypersensitivity to the constituents of the IMP - dimethyl
             sulfoxide (DMSO) or human serum albumin (HSA)

          -  History of severe alcohol or drug abuse within 3 months of screening

          -  Hb% &lt; 10 gm% for males, Hb% &lt; 9 gm% for females, serum creatinine ≥ 2mg%, serum Total
             Bilirubin ≥2mg%

          -  Pregnant and lactating women

          -  Patients tested positive for HIV 1, HCV, HBV, CMV, RPR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Anirban Chatterjee</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMRI Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Anita Dhar</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Rajkumar M</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanley Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Radhakrishnan R</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sri Ramchandra Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Vidyasagaran T</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madras Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Alfred Augustine</last_name>
    <role>Principal Investigator</role>
    <affiliation>KMC, Mangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Sanjay Desai</last_name>
    <role>Principal Investigator</role>
    <affiliation>M. S. Ramaiah Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Rajiv Parakh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medanta - The Medicity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Santanu Dutta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nightingale Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Murali Krishna</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sri Jayadeva Institute of Cardiovascular Sciences &amp; Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgical Disciplines, All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Peripheral Vascular and Endovascular Sciences, Medanta - The Medicity</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular and Endovascular Surgery, M. S. Ramaiah Medical College and Hospitals</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560066</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peripheral Vascular Surgery, Sri Jayadeva Institute of Cardiovascular Sciences &amp; Research</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560069</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, KMC, Mangalore</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery, Madras Medical College</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery, Sri Ramchandra Medical College</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600116</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery, Stanley Medical College</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>91-44-24732266</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Vascular Surgery, AMRI Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nightingale Hospital</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700071</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2011</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical limb ischemia</keyword>
  <keyword>Buerger's disease</keyword>
  <keyword>Critical limb ischemia due to Buerger's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Thromboangiitis Obliterans</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

